Antiresorptive effect of denosumab in the treatment of osteoporosis in patients with rheumatoid arthritis

摘要

Objectives: to compare the antiresorptive activity of denosumab and oral bisphosphonates in patients with rheumatoid arthritis and osteoporosis using beta-CrossLaps and osteocalcin. Patients and methods: 16 patients were treated with denosumab, 13 patients - bisphosphonates, 13 patients - control group. The quantitative determination of beta-CrossLaps and osteocalcin was carried out by all. Results: The level of beta-CrossLaps (median 861.6 pg / ml vs. 724.6 pg / ml, ρ = 0.049) and osteocalcin (median 13.9 vs 8.49, ρ = 0.047) in a month. Conclusions: denosumab had showed better antiresorptive activity compared with BF and it had registered within 1 month after the start of treatment reliably.